Jacqueline E Schein
Overview
Explore the profile of Jacqueline E Schein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
8898
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao E, Shen Y, Pleasance E, Kasaian K, Leelakumari S, Jones M, et al.
Clin Cancer Res
. 2017 Dec;
23(24):7521-7530.
PMID: 29246904
Recent studies have identified mutation signatures of homologous recombination deficiency (HRD) in over 20% of breast cancers, as well as pancreatic, ovarian, and gastric cancers. There is an urgent need...
2.
Morrissy A, Cavalli F, Remke M, Ramaswamy V, Shih D, Holgado B, et al.
Nat Genet
. 2017 Apr;
49(5):780-788.
PMID: 28394352
Spatial heterogeneity of transcriptional and genetic markers between physically isolated biopsies of a single tumor poses major barriers to the identification of biomarkers and the development of targeted therapies that...
3.
Kasaian K, Wiseman S, Walker B, Schein J, Hirst M, Moore R, et al.
Cold Spring Harb Mol Case Stud
. 2016 May;
2(2):a000729.
PMID: 27148585
Medullary thyroid cancer (MTC) is a malignancy of the calcitonin-producing parafollicular cells of the thyroid gland. Surgery is the only curative treatment for this cancer. External beam radiation therapy is...
4.
Molecular etiology of an indolent lymphoproliferative disorder determined by whole-genome sequencing
Parker J, Shen Y, Pleasance E, Li Y, Schein J, Zhao Y, et al.
Cold Spring Harb Mol Case Stud
. 2016 May;
2(2):a000679.
PMID: 27148583
In an attempt to assess potential treatment options, whole-genome and transcriptome sequencing were performed on a patient with an unclassifiable small lymphoproliferative disorder. Variants from genome sequencing were prioritized using...
5.
Morrissy A, Garzia L, Shih D, Zuyderduyn S, Huang X, Skowron P, et al.
Nature
. 2016 Jan;
529(7586):351-7.
PMID: 26760213
The development of targeted anti-cancer therapies through the study of cancer genomes is intended to increase survival rates and decrease treatment-related toxicity. We treated a transposon-driven, functional genomic mouse model...
6.
Kasaian K, Wiseman S, Walker B, Schein J, Zhao Y, Hirst M, et al.
BMC Cancer
. 2015 Dec;
15:984.
PMID: 26680454
Background: Anaplastic thyroid carcinoma is the most undifferentiated form of thyroid cancer and one of the deadliest of all adult solid malignancies. Here we report the first genomic and transcriptomic...
7.
Linehan W, Spellman P, Ricketts C, Creighton C, Fei S, Davis C, et al.
N Engl J Med
. 2015 Nov;
374(2):135-45.
PMID: 26536169
Background: Papillary renal-cell carcinoma, which accounts for 15 to 20% of renal-cell carcinomas, is a heterogeneous disease that consists of various types of renal cancer, including tumors with indolent, multifocal...
8.
Bose P, Pleasance E, Jones M, Shen Y, Chng C, Reisle C, et al.
Oral Oncol
. 2015 Jul;
51(9):e71-5.
PMID: 26173781
No abstract available.
9.
Kasaian K, Chindris A, Wiseman S, Mungall K, Zeng T, Tse K, et al.
J Clin Endocrinol Metab
. 2015 Jan;
100(4):E611-5.
PMID: 25625803
Context And Objective: Oncocytic thyroid carcinoma, also known as Hürthle cell thyroid carcinoma, accounts for only a small percentage of all thyroid cancers. However, this malignancy often presents at an...
10.
Jamshidi F, Pleasance E, Li Y, Shen Y, Kasaian K, Corbett R, et al.
Oncologist
. 2014 May;
19(6):623-30.
PMID: 24807916
Extraordinary advancements in sequencing technology have made what was once a decade-long multi-institutional endeavor into a methodology with the potential for practical use in a clinical setting. We therefore set...